Search

for
Search:

Research

5 / 1000+ results

research Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome

294 citations , March 2016 in “European journal of cancer”

This study found that neoadjuvant chemotherapy followed by interval debulking surgery led to better quality of life and lower perioperative morbidity compared to primary debulking surgery in advanced epithelial ovarian cancer patients with high tumor load.

research Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma

28 citations , September 2014 in “Journal of Veterinary Internal Medicine”

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment

3 citations , April 2025 in “American Journal of Clinical Dermatology”

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).

2 citations , May 2011 in “Journal of Clinical Oncology”

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas

1 citations , November 2025 in “Neuro-Oncology”

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

View more "phase ii" in research →

Community Join

5 / 1000+ results

community Phase II topical dut study - outperforms oral fin with a minor DHT reduction

in Research/Science 61 upvotes 7 months ago

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

community So why did the first pyrilutamide phase III fail?

4 upvotes 1 month ago

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

community GT20029 phase II results release date?

15 upvotes 2 years ago

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

community Breezula Phase III 12-Month Data Released by Cosmo Pharma

42 upvotes 5 months ago

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

community Pyrilutamide phase III clinical trial results released

in Research/Science 31 upvotes 2 years ago

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

View more "phase ii" in community →

Learn

8 / 801 results

learn GT20029

research compound made to degrade androgen receptors in scalp

When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.

learn Clascoterone

Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

learn Pyrilutamide

What is pyrilutamide, and how does it help with androgenic alopecia or hair loss caused by DHT? Pyrilutamide (KX-826) is an investigational topical antiandrogen designed to block DHT at the androgen receptor in the scalp rather than lower DHT in the blood. Its sponsor has announced positive Phase III top-line results in China, but none of the data are peer-reviewed and it is not approved as a medicine anywhere.
Can pyrilutamide be used by both men and women, or only in specific cases? Pyrilutamide (KX-826) is an investigational topical anti-androgen that has been trialled in both men and women, but it is not approved for hair loss anywhere; the company reports that its China Phase III trial in men met its primary endpoint, but the data come from sponsor announcements rather than peer-reviewed journals, and long-term safety is unknown.

learn HMI-115

much-hyped research compound targeting prolactin receptor in scalp

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn Hair Multiplication

extract, clone, and reinsert your own hair cells

learn Overview

View more "phase ii" in learn →

Clinics

2 / 14 results

Experts

4 / 4 results